跳至主要内容
临床试验/CTRI/2023/05/052593
CTRI/2023/05/052593招募中Unknown

Randomized Control Trial to study the safety and efficacy of dual blockade of Renin Angiotensin Aldosterone System (RAAS) in Primary Glomerular diseases.

Department of Nephrology0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with primary glomerular diseases â?? MN, FSGS, IgAn, iMPGN, MCD
  • 2. Patients with who have received single RAAS blocking agent (LOSARTAN 100 mg) for atleast 4 weeks and having proteinuria more than 500 mg/day
  • 3. Age >12 years
  • 4. Either sex

排除标准

  • 1. Secondary glomerulonephritis.
  • 2. Prior history of angioedema
  • 3. Bilateral renal artery stenosis
  • 4. Pregnancy
  • 5. Serum Potassium more than 5.1 mmol/L
  • 6. eGFR < 30 ml/min

研究者

相似试验